Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ranolazine
Drug ID BADD_D01915
Description Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities.[A189234] Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms.[L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440]
Indications and Usage Ranolazine is indicated for the treatment of chronic angina. It can be used alone or in conjunction with nitrates, beta-blockers, angiotensin receptor blockers, anti-platelet drugs, calcium channel blockers, lipid-lowering drugs, and ACE inhibitors.[L3580] Ranolazine has also been used off-label for the treatment of certain arrhythmias, including ventricular tachycardia, however, this use is not strongly supported by scientific evidence.[A174940] Ranolazine has also been studied for the treatment of acute coronary syndrome, microvascular coronary dysfunction, arrhythmia, and glycemic control, which are not yet approved indications.[A174898,L3580]
Marketing Status approved; investigational
ATC Code C01EB18
DrugBank ID DB00243
KEGG ID D05700
MeSH ID D000069458
PubChem ID 56959
TTD Drug ID D03HYQ
NDC Product Code 50370-0019; 61958-1004; 69367-294; 70625-207; 71610-518; 59651-009; 64552-4024; 67651-0224; 68180-355; 70756-703; 15308-0718; 29300-296; 29300-297; 50228-424; 68180-354; 69367-293; 70771-1500; 63304-017; 68462-319; 69097-221; 72319-021; 40006-043; 42765-048; 73680-0012; 27241-126; 42385-964; 50268-722; 50268-723; 59651-010; 63304-018; 65162-379; 67877-525; 69097-222; 72578-065; 53747-042; 65862-981; 27241-125; 66039-943; 67835-0011; 42571-324; 61958-1003; 63552-142; 72640-001; 31722-668; 31722-669; 43353-880; 47335-624; 68462-320; 70771-1499; 71205-867; 72319-022; 47621-304; 51604-1154; 62512-0076; 67651-0258; 42291-774; 42385-963; 42571-325; 47335-625; 65162-376; 71205-868; 72578-064; 48087-0082; 63552-143; 42291-773; 50228-423; 60687-549; 67877-526; 70625-206; 70756-704; 11014-0108; 48087-0106; 49711-1518; 64220-213; 65372-1190; 70966-0008; 45963-418; 45963-419
UNII A6IEZ5M406
Synonyms Ranolazine | N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide | Renolazine | Ranolazine Hydrochloride | Hydrochloride, Ranolazine | Ranolazine Dihydrochloride | Dihydrochloride, Ranolazine | Ranolazine HCl | HCl, Ranolazine | Ranexa | RS 43285-193 | RS 43285 193 | RS 43285193 | RS 43285 | 43285, RS | RS-43285 | RS43285
Chemical Information
Molecular Formula C24H33N3O4
CAS Registry Number 95635-55-5
SMILES CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hernia08.01.04.0010.000284%Not Available
Hypercholesterolaemia14.08.01.0010.000569%Not Available
Hyperglycaemia14.06.02.002; 05.06.02.0020.000427%
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkalaemia14.05.03.0010.000910%
Hypertension24.08.02.0010.003129%
Hypoaesthesia23.03.03.081; 17.02.06.0230.002987%Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.001536%
Hyponatraemia14.05.04.0020.000569%
Hypotension24.06.03.0020.006003%
Hypotonia17.05.02.002; 15.05.04.0080.000284%Not Available
Impaired healing08.03.02.0010.000626%Not Available
Incontinence07.01.06.011; 20.02.02.004; 17.05.01.0060.000967%Not Available
Initial insomnia17.15.03.005; 19.02.01.0050.000967%Not Available
Insomnia19.02.01.002; 17.15.03.0020.006174%
Joint swelling15.01.02.004--Not Available
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.0030.000427%
Left ventricular failure02.05.02.0010.000427%Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukopenia01.02.02.001--Not Available
Libido increased21.03.02.007; 19.08.03.0020.000967%
Lip swelling10.01.05.005; 07.05.04.005; 23.04.01.0070.001394%Not Available
Loss of consciousness17.02.04.0040.001906%Not Available
Lung disorder22.02.07.0010.000427%Not Available
Lymphadenopathy01.09.01.0020.000626%Not Available
Menopausal symptoms21.02.02.002--Not Available
Mental impairment17.03.03.002; 19.21.02.0030.000768%Not Available
Mitral valve incompetence02.07.01.0020.000284%Not Available
Multiple sclerosis17.16.01.001; 10.04.10.0080.000284%Not Available
Muscle spasms15.05.03.004--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 8 Pages